about
MPNs as Inflammatory Diseases: The Evidence, Consequences, and PerspectivesThe Role of Reactive Oxygen Species in Myelofibrosis and Related NeoplasmsA 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic MyelofibrosisA new internet-based tool for reporting and analysing patient-reported outcomes and the feasibility of repeated data collection from patients with myeloproliferative neoplasms.Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia.Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia.Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients.Effect of thrombopoietin-receptor agonists on circulating cytokine and chemokine levels in patients with primary immune thrombocytopenia (ITP).Risk of lymphoma and solid cancer among patients with rheumatoid arthritis in a primary care setting.Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders.A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burdenWhole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression.MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.WHO classification 2008 of myeloproliferative neoplasms: a workshop learning effect--the Danish experience.Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option.Whole-exome sequencing and genome-wide methylation analyses identify novel disease associated mutations and methylation patterns in idiopathic hypereosinophilic syndrome.A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group.Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence.Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents.Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?The role of cytokines in the initiation and progression of myelofibrosis.Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms.Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort study.Smoking as a contributing factor for development of polycythemia vera and related neoplasms.Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.A retrospective analysis of the impact of treatments and blood counts on survival and the risk of vascular events during the course of polycythaemia vera.Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib.A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials.Prevalence and clinical significance of neutropenia discovered in routine complete blood cell counts: a longitudinal study.Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera.
P50
Q26775996-0B89E378-B026-4BF0-99A7-96F6C09DB876Q26779929-F167D45E-1BC0-4866-B5E5-06C30FD1F293Q28553797-49A15703-8277-44F4-A769-5E20D30514C2Q30992878-09CD548F-E0C3-4A7D-9F9E-D2F87AA88AEDQ33328174-DBA20AD0-3762-488C-A72A-687BFBF2C585Q33338419-0C57AD8F-FD61-4BA9-A18B-2CA4A9A07A05Q33365619-732C3BFB-9191-4FD5-92F7-C661FD4C310DQ33397092-9E5B89CE-1398-4D35-B2D5-B889F9543C01Q33398815-57DAC0EF-4A4A-4261-84D9-ACFEC79AC3B4Q33405127-E87ADD02-8FCA-4CFC-BAE1-D5FB5B944A39Q33422507-51192DD7-4350-471F-BCED-36E277208E20Q33436570-614860B0-C0FD-4A8C-8437-3860A2530130Q33734256-81E26C12-BF85-45DF-BA5F-1D61E25A17CAQ34171747-09F7CBD9-2D47-404A-AE7C-46E46C3A1BA1Q34189794-824AB76F-1418-4AF3-8C56-6E6690805CA5Q34514329-59BC08BF-97C1-4633-BB82-F093458FC5C0Q34775393-4511BE54-73F1-48EC-BB59-C3BA71575FC0Q35705470-AF8706B2-B3D2-41B0-A6E6-1D3E5FFDE74DQ36169641-C667FC8B-1A14-44D1-9ACC-5AE1081B4178Q36398850-18297628-1CD4-4309-BF75-A6CFBE675265Q36462675-EA1CCCF9-B7DA-46F2-8AF1-13DB66860EE3Q36562094-FAA9EAA8-AF2A-4394-BFD3-C5AED3933BDFQ36717896-F9998DEB-CB6C-4D41-838F-8364C50F95E5Q37163590-6788FA2F-E2BF-4D6F-87FD-D8E4DE93558BQ37231416-7BC81181-5D8F-4F21-9B2A-CA46134658BEQ37412790-97A6C6E4-C324-40E5-81E7-8E1B053AFB99Q37682689-4173FB3C-AA6A-4326-B53B-67D7F554D50EQ38061746-FFF9DD78-163B-48FF-9610-5C23B8676CE7Q38082073-443DDBEF-EE69-4EED-B3E3-FD6CA66007C8Q38187674-32AE8940-46F5-4DE3-BD9C-7F0093954CEAQ38384255-D48FECC9-3F04-4E45-A30B-04AFAA633721Q38606278-3E30368B-9517-4321-802A-831C935DC5E2Q38706624-1908B218-28F7-46CE-9FC0-76C98AB98178Q38725723-F72440D5-DD7A-4CA1-AF84-C164A4A2AA21Q38802882-45F73089-9594-4835-B734-695111DF8854Q39237430-D78F35D2-DC0F-4C1A-9C22-C39CCA225FA0Q39403830-FB7E4C4F-9FB4-4B97-BE00-CF50CA4CB4FFQ39979643-720E7702-9F2C-4CAE-A503-88D9A323CD6AQ40081960-954A5693-56C5-46E3-9173-2D8CC0C37160Q40091659-A2639CEA-4EE6-4DD1-9BA5-C8864D92B9EB
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Hans K. Hasselbalch
@ast
Hans K. Hasselbalch
@en
Hans K. Hasselbalch
@es
Hans K. Hasselbalch
@nl
Hans K. Hasselbalch
@sl
type
label
Hans K. Hasselbalch
@ast
Hans K. Hasselbalch
@en
Hans K. Hasselbalch
@es
Hans K. Hasselbalch
@nl
Hans K. Hasselbalch
@sl
prefLabel
Hans K. Hasselbalch
@ast
Hans K. Hasselbalch
@en
Hans K. Hasselbalch
@es
Hans K. Hasselbalch
@nl
Hans K. Hasselbalch
@sl
P106
P1153
35402388700
P21
P31
P496
0000-0003-3936-8032